Must-read for patients: Overview of basic information on the Chinese instructions for adagrasib

1. Name: Adagrasib, Adagrasib, KRAZATI

2. Who can take adagrasib? Indications?

Adagrasib (Adagrasib) is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic cancer (NSCLC) who have received at least one prior systemic therapy, as determined by an FDA-approved test. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR), and continued approval may be contingent on verification and description of clinical benefit in confirmatory trials.

3. What are the side effects of adagrasib?

Common side effects of adagrasib include nausea, diarrhea, vomiting, fatigue, musculoskeletal pain, liver toxicity, renal impairment, edema, and dyspnea. The most common grade 3 or 4 laboratory abnormalities are lymphopenia, decreased hemoglobin, increased alanine aminotransferase, increased aspartate aminotransferase, hypokalemia, hyponatremia, increased lipase, and decreased leukocytes.

4. How should you take adagrasib?

The recommended dose of adagrasiib is 600 mg orally twice daily until disease progression or unacceptable toxicity. Take adagrasiib at the same time every day with or without food. Swallow the tablet whole. Do not chew, crush, or split tablets.

1. Medication management: Based on the presence of KRAS G12C mutations in plasma or tumor specimens, patients are selected to treat locally advanced or metastatic NSCLC with adagrasib. If no mutations are detected in the plasma sample, tumor tissue is tested. If vomiting occurs after taking adagrasiib, do not take additional doses. Resume dosing at the next scheduled time. If a dose is missed inadvertently, the dose should be skipped if more than 4 hours have passed since the intended administration time. Resume dosing at the next scheduled time.

5. How to store adagrasib?

Adagrasib tablets can be stored inAt room temperature, 20°C to 25°C (68°F to 77°F). Allow temperature to fluctuate between 15°C to 30°C (59°F to 86°F).

6. How does Adagraxibu work?

Adagrasib is an irreversible inhibitor of KRAS G12C that covalently binds to the mutated cysteine in KRAS G12C and locks the mutated KRAS protein in its inactive state, thereby preventing downstream signaling without affecting the wild-type KRAS protein. Adagarasib inhibits tumor cell growth and viability in cells harboring the KRAS G12C mutation and causes tumor regression in a KRAS G12C-mutated tumor xenograft model with minimal off-target activity.

7. What will happen if you take too much adagrasiib?

Toxicity information on adagrasib is not readily available. Overdose patients are at increased risk for serious adverse reactions, such as hepatotoxicity, gastrointestinal adverse reactions, and QTc interval prolongation. Symptomatic support measures are recommended.

8. Who cannot use Adagrasib?

Adagarasib is contraindicated in patients who are allergic to adagrasib and other ingredients. Based on animal studies, adagrasib may damage the fertility of women and men of reproductive potential, and patients should use the drug under the guidance of a doctor.